Advertisement
Table 1 Clinicopathological characteristics of the 152 breast cancer patients
| Characteristic | Number (%) |
|---|---|
| Gender | |
| Female | 152 (100) |
| Male | 0 (0) |
| Age | |
| ≤55 | 80 (52.6) |
| >55 | 72 (47.4) |
| Mean (±SD) | 56.0 (12.4) |
| Tumor size (T-status) | |
| T1 (0–20 mm) | 77 (50.7) |
| T2 (20–50 mm) | 68 (44.7) |
| T3 (>50 mm) | 7 (4.6) |
| (T2-T3) | (75 (49.3)) |
| Grade | |
| G1 (well differentiated) | 21 (13.8) |
| G2 (moderately differentiated) | 53 (34.9) |
| (G1-G2) | (74 (48.7)) |
| G3 (poorly differentiated) | 78 (51.3) |
| Estrogen receptor (ER) status | |
| Negative | 35 (23.0) |
| Positive | 117 (77.0) |
| Progesterone receptor (PR) status | |
| Negative | 51 (33.6) |
| Positive | 101 (66.4) |
| Human epidermal growth factor receptor 2 (HER2) status | |
| Negative | 137 (90.1) |
| Positive | 15 (9.9) |
| Hormone receptor (HR) negative status (ER/PR negative) | |
| Yes | 34 (22.4) |
| No | 118 (77.6) |
| Triple negative (TN) status (ER/PR/HER2 negative) | |
| Yes | 29 (19.1) |
| No | 123 (80.9) |
| Lymph node (N) status | |
| N0 (0 lymph nodes) | 98 (64.5) |
| N1 (1–3 lymph nodes) | 40 (26.3) |
| N2 (4–9 lymph nodes) | 11 (7.2) |
| N3 (≥10 lymph nodes) | 3 (2.0) |
| (N1-N2-N3)a | (54 (35.5)) |
| Molecular tumor subtypes (PAM50 signatures) | |
| Basal | 25 (16.7) |
| HER2 enriched | 15 (10.0) |
| Luminal A | 63 (42.0) |
| Luminal B | 39 (26.0) |
| Normal-like | 8 (5.3) |
